Synthetic Biology and Bioprocessing Market Reaches Multi-Billion Scale with High-Throughput Fermentation and Engineered Microbes Driving Innovation

Ottawa, Feb. 09, 2026 (GLOBE NEWSWIRE) -- According to data published by Precedence Research, the global Synthetic Biology and Bioprocessing sector is driven by companies such as Amyris ($570M revenue), Ginkgo Bioworks ($478M revenue), and Novozymes (€2.37B revenue), supported by high-throughput microbial engineering, precision fermentation capacities exceeding 2,000 m³, and thousands of commercialized enzymes and bio-based molecules. Government programs in the USA, EU, UK, China, and Japan provide billions in funding to accelerate innovation and industrial adoption.

The Synthetic Biology and Bioprocessing market is rapidly scaling with high-capacity fermentation, engineered strains, and enzyme production platforms, underpinned by multi-billion-dollar investments and government support, data published by Precedence Research.

Invest in Our Premium Strategic Solution: https://www.precedenceresearch.com/request-consultation/42

Key Company Insights

Bioprocessing Infrastructure & Capacity

Government & Public Sector Funding

Notes: Government support through DARPA, DOE, NSF, Horizon Europe, UKRI, and other agencies fuels industrial and synthetic biology R&D, enabling high-throughput strain engineering, enzyme innovation, and large-scale biomanufacturing.

Market Insights

How Precedence Research Can Help

Precedence Research provides deep insights and actionable data for Synthetic Biology & Bioprocessing stakeholders:

Email: sales@precedenceresearch.com

USA: +1 8044 419344 | APAC: +61 4859 81310 / +91 87933 22019 | Europe: +44 7383 092 044

Precedence Research – Transforming Complex Data into Strategic Decisions